Phiusion Labs announces a strategic distribution partnership with Proteos Biotech S.L.

Phiusion Labs Inc. announced a strategic partnership with Proteos Biotech S.L.. This partnership will facilitate the distribution of the PBSerum® product portfolio across the United States and Canada.

The PBSerum® portfolio of enzymatic solutions focuses on aesthetic skin quality and will be introduced to physicians across North America, expanding the range of tools available for cosmetic and aesthetic practices.

PBSerum® is based on patented recombinant enzyme technology designed to interact with components of the extracellular matrix. These highly purified enzymes are formulated to act selectively within the tissue environment, supporting cosmetic approaches aimed at improving the appearance and overall quality of the skin.

Distinct from conventional aesthetic modalities that focus primarily on volume replacement or mechanical or energy-based stimulation, the PBSerum® portfolio represents a biologically inspired approach centered on skin quality. By incorporating enzymatic activity into aesthetic treatment protocols, practitioners gain additional options to address visible aspects of skin texture that may not be fully addressed through traditional techniques.

This approach reflects an emerging direction within aesthetic medicine – one that places increasing emphasis on skin quality, overall appearance, and complementary treatment strategies.

“The United States and Canada represent a key strategic market for us. We are pleased to partner with Phiusion Labs Inc., whose experience in both physician education and market development makes them an ideal partner to support the introduction of PBSerum®,” said Juan Ramón Muñoz Montaño, CEO of Proteos Biotech S.L.

Ario Khoshbin, Founder and CEO of Phiusion Labs Inc., added:
“Having worked in the medical aesthetics field for over two decades, including founding Prollenium Medical Technologies and growing it into a global player in aesthetics, it is clear that practitioners are increasingly seeking solutions that go beyond traditional approaches. This partnership introduces a differentiated and biologically inspired approach to aesthetic medicine in North America. PBSerum® provides physicians with an additional tool to support aesthetic treatment plans, complementing existing modalities while expanding treatment possibilities.”

Proteos Biotech S.L. has developed PBSerum® with a focus on precision and versatility, enabling its use across a range of aesthetic applications. Phiusion Labs Inc. will support the rollout through structured physician education, training programs, and clinical integration initiatives.